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NexagonSkin lesions are common events and we have evolved to rapidly heal them in order to maintain homeostasis
and prevent infection and sepsis. Most acute wounds heal without issue, but as we get older our bodies be-
come compromised by poor blood circulation and conditions such as diabetes, leading to slower healing. This
can result in stalled or hard-to-heal chronic wounds. Currently about 2% of the Western population develop a
chronic wound and this ﬁgure will rise as the population ages and diabetes becomes more prevalent [1]. Pa-
tient morbidity and quality of life are profoundly altered by chronic wounds [2]. Unfortunately a signiﬁcant
proportion of these chronic wounds fail to respond to conventional treatment and can result in amputation
of the lower limb. Life quality and expectancy following amputation is severely reduced. These hard to
heal wounds also represent a growing economic burden on Western society with published estimates of
costs to healthcare services in the region of $25B annually [3]. There exists a growing need for speciﬁc and
effective therapeutic agents to improve healing in these wounds. In recent years the gap junction protein
Cx43 has been shown to play a pivotal role early on in the acute wound healing process at a number of dif-
ferent levels [4–7]. Conversely, abnormal expression of Cx43 in wound edge keratinocytes was shown to un-
derlie the poor rate of healing in diabetic rats, and targeting its expression with an antisense gel restored
normal healing rates [8]. The presence of Cx43 in the wound edge keratinocytes of human chronic wounds
has also been reported [9]. Abnormal Cx43 biology may underlie the poor healing of human chronic wounds
and be amenable therapeutic intervention [7]. This article is part of a Special Issue entitled: The Communicat-
ing junctions, composition, structure and characteristics.
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Our skin is the largest organ of the body and its maintenance is es-
sential for survival. In the avascular epidermis gap junctions areommunicating junctions, com-
ier B.V. Open access under CC BY liceessential for the passage of nutrients between cells as well as gaseous
exchange. There are a wide variety of different connexin types that
have been reported to be expressed at different levels in mammalian
skin, including Cx26, 30, 30.3, 31, 31.1, 32, 37, 40, 43 and 45 [10–19].
The reasons for the widespread expression and the relative impor-
tance of the different connexin types remains obscure but the re-
quirement for the normal functioning of several different connexins
has been made clear by the diseases that arise following point muta-
tions in certain types of connexins, e.g., hystrix-like ichthyosis withnse.
Table 1
Summary of connexin dynamics in acute wound healing of normal and diabetic rodent
skin.
Cx43 Cx31.1 Cx26 Cx30
Connexin dynamics in rodent skin acute wound healing
Migratory phase
Epidermis
Leading edge keratinocytes
Dermismigratingﬁbroblasts
Inﬂammatory phase
Blood vessels
Mast cells
Neutrophils
Macrophages
Granulation tissue phase
Fibroblasts
Epidermal revision phase
Keratinocytes
STZ diabetic rat wounds
Non-Migratory phase 1 day
after wounding
Non-migrating Epidermis over a wide
zone
over a wide
zone
Leading edge keratinocytes
Dermis non- migrating
ﬁbroblasts
Migratory phase 2 days after
wounding
Epidermis over a wide
zone
over a wide
zone
Leading edge keratinocytes
Dermismigratingﬁbroblasts
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winkel syndrome and erythrokeratoderma variabilis (EKV),
[16,17,19–21].
Whilst many different types of connexin have been detected in the
skin, most are expressed at very low levels. However, connexins 43,
30 and 26 are found to dominate. In rodent skin Cx43 is by far the
most ubiquitous and is found in dermal ﬁbroblasts, blood vessels,
and appendages such as sweat glands, sebaceous glands, hair follicles,
and mast cells and activated leukocytes as well as epidermal kerati-
nocytes [4,17,22]. Connexins 26 and 30 are not found in the dermal
ﬁbroblasts but are reportedly expressed in the epidermal spinous
layers of rodent skin. Cx26 is more strongly expressed in the basal
layers of rodent epidermis, whereas Cx30 is expressed more strongly
in suprabasal layers of human and porcine skin, as well as hair follicle
keratinocytes [18]. Cx31.1 can be detected in skin granular layer cells
undergoing death, similar to the expression seen in cells about to die
in the atretic follicles of the ovary and it might be possible that this
connexin serves to coordinate cell death in these situations [4,14,23].
2. Wounding brings about rapid changes in connexin expression
in the injured epidermis
Any wound to the skin sets off a series of four interrelated and
overlapping processes (haemostasis, inﬂammation, proliferation and
migration, followed by scar tissue remodelling) designed to prevent
infection and bring about wound closure [24]. Haemostasis processes
take place in the ﬁrst few hours and are followed by inﬂammation
that rapidly increases and lasts for several days. As these events pro-
gress there are concomitant changes in the expression of different
connexins (Table 1). The ﬁrst changes in epidermal connexins can
be observed about 6 h after injury in rodent skin wounds, at which
time downregulation of both Cx43 and 31.1 can be observed in
wound edge keratinocytes. The downregulation continues so that vir-
tually none is detectable within the ﬁrst 1–2 days after wounding
[4,25,26]. This downregulation is correlated with keratinocytes
adopting a migratory phenotype as they start to crawl across the
wound bed to close the epidermal breach. Conversely whilst Cx43
and 31.1 are turned off in wound edge keratinocytes, Cx30 and 26,
which are normally expressed at low levels, are greatly upregulated,
and remain so in the leading edge keratinocytes during the process
of migration, only returning to normal when the wound is closed
[4]. Although Cx43 is greatly reduced in actively migrating leading
edge keratinocytes, it is found at relatively high levels a few cell
rows back where cells are actively proliferating [4,15,25]. Very similar
connexin dynamics are seen the healing response in explants of human
skin despite the subtle different connexin distributions between the
laminae. A downregulation of Cx43 occurs inwound edge keratinocytes
as early as 5 h after wounding and by 24 h Cx43 is hard to detect whilst
Cx26 and Cx30 have greatly increased in its place [9,27].
Interestingly, whilst Cx30 and 26 can interact and form gap junc-
tions with each other, they do not do so with Cx43 and have very dif-
ferent coupling and dye transfer properties [28]. It is therefore
possible that migrating keratinocytes require different communica-
tion properties and may even form a communication compartment
exclusive to the leading edge cells which does not communicate
with the cells following a few rows back. Such communication com-
partments have previously been proposed to coordinate the morpho-
genic movements of tissues in embryonic development and also
wound healing [24,27,29,30]. A role for protein kinase C has also
been proposed in phosphorylating Cx43 serine 368 at the wound
edge in order to decrease its communication, a hypothesis which is
supported by dye transfer studies which show restriction in commu-
nication between wound edge cells [27,31–34]. However, these
changes are all transient and as soon as the migration is complete
and the wound edges have joined up, connexin levels start to return
to their normal expression pattern and distribution [4,8]. The reasonfor these dynamic changes in connexin expression patterns and the
precise communication requirements during the healing process
still remain to be fully determined. However, it appears that it is not
a complete absence of communication that is required for keratino-
cyte migration but an absence of Cx43 [4,9].
Whymight an absence of Cx43 frommigrating cells be desirable in
order to promote migration? There are several potential explanations
for this. The cytoplasmic tail of Cx43 can bind to an array of other
junctional and cytoskeletal proteins, either directly via a PDZ domain
or indirectly via other proteins such as membranous Cadherins, Zonu-
lar Occludin-1 (ZO-1), α- and β-catenin, as well as cytoskeletal mi-
crotubules and actin [35–42]. Such interactions may affect both cell
adhesion and cytoskeletal dynamics and therefore cell migration
and wound healing. However, some of the interactions are with tran-
scription factors such as β-catenin, and binding to it may keep β-
catenin at the cell membrane, preventing it from inﬂuencing gene ex-
pression. Indeed, it has been proposed that Cx43 forms the centre of a
protein complex or “nexus” acting as a master gene that can inﬂuence
expression of other over 300 other genes [43,44]. If so, the inﬂuence
from Cx43 may not just be at the level of protein–protein interactions
but may also have inﬂuence at the transcriptional level. This would
involve a role that is potentially independent from its functions of
cell–cell communication as a gap junction channel. In sum, Cx43
may inﬂuence wound healing in different ways including affecting
the expression of other genes and proteins that can inﬂuence
wound healing.
3. Dermal connexin responses to injury
Similar to keratinocytes, wound edge dermal ﬁbroblasts downre-
gulate Cx43 in the ﬁrst 24–48 h after wounding as they start to mi-
grate into the wound bed and form new granulation tissue [6].
However, whilst Cx43 is downregulated in ﬁbroblasts it is upregu-
lated in the endothelial cells of blood vessels as they become inﬂamed
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detected in the ﬁrst few hours after injury and is maintained at a
high level throughout the inﬂammatory period in a similar way to
that seen following central nervous system injury [4,6,45]. The upre-
gulation of Cx43 is likely to be brought about by the proinﬂammatory
signals being released at the wound site and this correlates with the
blood vessels becoming leaky to leukocytes, proteins and ﬂuids
which in turn cause the dermis to swell.
The inﬂammatory response has long been thought to be central to
the tissue repair process though the positive nature of this role is now
being questioned [46]. Inﬂammatory signals come from a variety of
sources starting with mast cells and degranulating platelets that are
forming a ﬁbrin clot to plug the wound. These release platelet derived
growth factor (PDGF) which in turn attracts neutrophils (which, in-
terestingly, also express Cx43) into the wound bed and surrounding
tissues where they release more inﬂammatory signals which in turn
recruits monocytes that transform into macrophages [46–49]. The re-
cruitment of the neutrophils serves a key role in the immediate de-
fence of any bacterial infection and prevents potential death by
sepsis. Macrophages in this setting serve to clear up spent neutrophils
and any other debris in and around the wound site whilst releasing
additional inﬂammatory signals such as transforming growth factor
beta 1 (TGF-β1) and ﬁbroblast growth factor 2 (FGF-2) [50].
The production of a strong inﬂammatory response is thought to
provide the signals to stimulate wound repair by transforming
wound edge ﬁbroblasts and keratinocytes into a migratory phenotype
that will crawl forward to close the wound and ﬁll the wound bed
with granulation tissue [50]. Research in recent years, however, has
produced evidence that may call this concept into question. For in-
stance, Smad3 knockout mice which have a lower than normal in-
ﬂammatory response to wounding, with signiﬁcantly less
neutrophils, are reported to show enhanced rates of epidermal
wound closure [51]. Similarly in the PU-1 knockout mouse, which
lacks mast cells, neutrophils and macrophages, wounds will heal at
a normal rate, again suggesting that an inﬂammatory response driven
by these cells is not essential for healing [52]. Indeed active depletion
of neutrophils from a wound site has also been reported to result in
faster re-epithelialization [53]. In a related manner, evidence from
embryonic wound healing studies on both animals and humans
shows that during the time before an embryo has developed the abil-
ity to mount an inﬂammatory response to injury, it will heal (by purse
string contraction rather than cells crawling forward) and it does so
without forming a scar [54–56]. This suggests that far from being es-
sential for triggering the onset of wound healing the inﬂammatory re-
sponse, it may in fact be contributing to ﬁbrosis and scar formation
[57]. Indeed large numbers of neutrophils at a wound site may do
more than just kill bacteria; the release of free radicals designed to
kill bacteria may also kill healthy cells in the intact surrounding tis-
sues [46].
However, the inﬂammation story is not so simple and there is con-
siderable evidence (though some of it contradictory) that shows ben-
eﬁcial effects from application of certain proinﬂammatory growth
factors, e.g., TGFβ-1, FGFs and PDGF, in promoting different aspects
of wound healing such as cell proliferation, migration and granulation
tissue formation [58,59]. Indeed, PDGF is the active ingredient the
FDA approved drug Regranex® (or becaplermin) and, although it
now has a “black box” warning due to cancer concerns, has been
reported to increase the rate of closure of diabetic ulcers by 10%
[59]. Conversely, by far the vast majority of the growth factors that
have entered clinical trials aimed at healing chronic ulcers have failed
to promote healing [59,60]. Getting the balance of inﬂammatory sig-
nalling right in both acute and chronic wound healing is clearly im-
portant. In terms of diabetic ulcers, it is unlikely that the addition of
any one growth factor, at a particular concentration and time is
going to be the answer to triggering and sustaining the healing of
these or other chronic wounds.4. The effects of targeting Cx43 expression at a site of skin injury
with antisense
Cx43 is by far the most ubiquitous connexin, being expressed in
very many cell types in both healthy and disease conditions, where
its presence is not always beneﬁcial. As mentioned earlier, in the
skin Cx43 is primarily expressed in keratinocytes, ﬁbroblasts, hair fol-
licles and blood vessels and, on wounding, it naturally slowly down-
regulates, being noticeable in 2–6 h but reaching a maximum in
24–48 h in wound edge cells as they become migratory [4,25,27,61].
Conversely Cx43 increases in blood vessels in and around the site of
injury in the ﬁrst few hours as they become inﬂamed and leaky
[4,45]. Cx43 has a relatively short half-life of about 1.5 h [62,63],
and its expression in skin has been targeted using a Cx43 speciﬁc an-
tisense oligodeoxynucleotide (Cx43asODN) in a thermo-reversible,
slow release, Pluronic gel. On topical application to a fresh wound in
rodent skin or cornea, it rapidly downregulates Cx43 protein levels
in the wound edge keratinocytes and ﬁbroblasts whilst reducing the
inﬂammatory upregulation of Cx43 in the blood vessels [5–7,64–
68]. The accelerated downregulation of Cx43 takes place in 2 h rather
than 24–48 h and has the effect of speeding the migration of keratino-
cytes and ﬁbroblasts, which results in closing the wound and forming
the granulation tissue considerably faster than untreated wounds
[5,6] (Fig. 1). Concomitantly, Cx43asODN has the effect of reducing
Cx43 upregulation that normally takes place in the blood vessels
around the site of injury, reducing their leakiness and the swelling
and oedema at the wound site of skin or in other sites such as central
nervous system lesions [5,45,69,70].
Macroscopically the effects of topical application of Cx43asODN
gel to acute wounds is pronounced and rapid; within 6 h treated
wounds are signiﬁcantly less red and swollen than control wounds,
release less exudate and stimulate less inﬂammatory leukocytes [5].
The beneﬁcial effects continue beyond the lifetime of the ODN itself
and both re-epithelialization and granulation tissue formation are
signiﬁcantly enhanced over the ensuing days, resulting in a thinner
ﬂatter scar [5,6]. Within the scar itself the collagen bundles appear
to be more basket-weave in appearance rather than the typical
aligned parallel bundles seen in most scars. Similarly the healing of
tail skin wounds in the inducible Cx43 knockout mouse show compa-
rable enhancements of healing [71,72]. Both the lack of Cx43 in Cx43
inducible knockout mice and treatment with Cx43asODN gel appear
to kick-start the acute wound healing process by targeting some of
its earliest events (Fig. 1). This results in accelerating some normal as-
pects of the healing response such as keratinocyte and ﬁbroblast mi-
gration, whilst reducing negative aspects such as inﬂammation,
enabling Cx43asODN to have beneﬁcial effects on healing long be-
yond the lifetime of the antisense itself.
In conjunction with reduced inﬂammation, the numbers of neu-
trophils both in and around the wound sites on days 1 and 2 after in-
jury [5,6] are reduced following application of Cx43asODN. This
reduction in neutrophil number may seem counterintuitive as their
role is to help eliminate bacterial infections in the wound and prevent
sepsis. However, the action of neutrophils can also be damaging to
the host tissues and reducing their numbers can in fact promote re-
epithelialization [53], which is very similar to our ﬁndings [5]. Re-
duced numbers of neutrophils are in turn followed by reduced num-
bers of macrophages [5,6] and the pro-inﬂammatory chemokines and
cytokines that they release such as chemokine ligand 2 (Ccl2) and
later on the cytokine tumour necrosis factor alpha (TNF-α). As both
of these cytokines normally attract even more neutrophils and mac-
rophages [73], their reduced expression helps explain the dampened
inﬂammatory response after Cx43asODN treatment of wounds. In ad-
dition, Cx43asODN treatment is likely to reduce Cx43 levels in neu-
trophils and activated leukocytes where its expression is involved in
cytokine and immunoglobulin release and further inﬂammatory cell
recruitment [74–76].
Fig. 1. Flow diagram of the effects of Cx43 antisense treatment on acute wound healing of normal rodent skin [5–7].
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pression of transforming growth factor beta-1 (TGFß-1) mRNA
2 days after wounding with elevated protein levels being found in
the nascent dermis and epidermis. This ﬁts well with the known ef-
fects of TGFß-1 on enhanced migration and proliferation [77] seen
in the epidermis and dermis [6]. Other effects of enhanced TGFß-1
may relate to enhanced collagen production as both TGFß-1 and de-
creased Cx43 are known to promote Col1 a1 expression [78,79],
which was found in treated wounds on days 2 and 7 after injury. En-
hanced collagen production results in the enhanced granulation tis-
sue maturation and angiogenesis [58] that is also seen in treated
wounds. Very ﬁne blood vessels are found throughout the granulation
tissue of treated wounds as early as 7 days after injury when blood
vessels are just beginning to enter the edges of the granulation tissue
of control wounds. Myoﬁbroblasts are also found to appear and thenclear 2–3 days earlier in the granulation tissue of treated wounds
thereby contributing to the faster maturation and smaller scar [6].
5. Connexins and diabetic wound healing
The onset of diabetes with associated hyperglycemia and oxida-
tive stress has deleterious effects on many organs of the body, but
particularly the vasculature, resulting in reduced delivery of oxygen
and nutrients to peripheral tissues. There have been a variety of in
vivo and in vitro studies relating to connexins and the diabetic vascu-
lature that have produced mixed and often contradictory ﬁndings
[80–84]. It has been reported that in diabetic endothelial cells, Cx37,
Cx40 and Cx43 either decrease or remain at the same level (though
not necessarily at the same time). However, there is a consensus
that there is a general decrease in blood vessel Cx43 and gap
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down of the blood vessels and cell death [80–84]. Studies of optic
nerve head blood ﬂow in diabetic rabbits was reported to show signif-
icantly decreased blood ﬂow under conditions of raised intraocular
pressure and a lack of normal blood vessel function, which appears
to be due to gap junctional dysfunction in the diabetic vessels [85].
In relation to this, in a variety of vascular cells, both in diabetic ani-
mals and when cultured in high glucose, a decrease gap junctional
communication whilst increasing Cx43 phosphorylation, potentially
by the action of PKC 9, has been reported [82,86–88]. Renal tissues
are also adversely affected by the onset of diabetes and again reports
on the effects of diabetes or in vitro high glucose culture conditions
are mixed and vary with cell type. For example, Cx43 has been
reported to both increase and decrease in diabetic kidney tubules
[89–91]. Collecting duct epithelial cells cultured in high glucose
were reported to have signiﬁcantly increased Cx43 protein [92]. The
mechanisms behind these different effects on connexin expression,
in different cell types, remain unknown.
We have found that in the skin of Streptozotocin (STZ) diabetic
rats there is a signiﬁcant alteration in connexin protein levels within
2 weeks of the onset of diabetes and long before peripheral neuropa-
thy sets in [7]. In the epidermis Cx43 and Cx26 protein and gap junc-
tional communication were signiﬁcantly decreased but in the dermis
Cx43 protein and communication increased. The differential effect on
connexin expression in different cell types in diabetes clearly varies
with the cell type and is not just a global downregulation of connex-
ins, as in some instances diabetes appears to result in enhanced con-
nexin expression [7].
Wound healing in patients with diabetes is perturbed and in
humans can often result in diabetic ulcers that are very difﬁcult to
heal [59,93,94]. Given the reduced levels of Cx43 in the epidermis of
STZ rats it might be assumed that re-epithelialization would be faster
as there is less Cx43 to downregulate. However, the Cx43 dynamics
following wounding of STZ skin are dramatically different to normal;
instead of decreasing in the leading edge keratinocytes in the ﬁrst
24 h, Cx43 is massively increased as a non-migratory bulb of kerati-
nocytes forms at the wound edge [7]. In these STZ diabetic rats kera-
tinocyte migration does not begin until Cx43 begins to downregulate
some 48 h later. Cx26 expression, on the other hand, does still elevate
in the diabetic rat leading edge cells but does so over a wider area
much further back from the wound edge than normal. It is possible
that both of these abnormal expression patterns contribute to differ-
ences in communication, or communication compartments in the
leading edge and thereby prevent or alter keratinocyte migration.
High levels of Cx26 in keratinocytes have also been associated with
hyperproliferative conditions [95]. Indeed, it was found that driving the
expression of Cx26 in Involucrin INV-Cx26 heterozygous mouse kerati-
nocytes delayed re-epithelialization and kept the epidermis in a hyper-
proliferative state, delaying remodelling and recovery of barrier
function [96]. Clearly the appropriate levels of connexin expression
are crucial for normal healing to take place. Attempts to normalize the
expression of Cx43 in STZ diabetic wound edge keratinocytes were
made by application of Cx43asODN gel to the wound at the time of in-
jury. This treatment prevented the abnormal Cx43postwounding upre-
gulation and the formation of a bulb of non-migratory cells, thereby
rescuing the rate of migration and returning healing rates to normal
and above [7]. It remains to be determined whether or not diabetic
humans show the same abnormal Cx43 response.
Today, throughout the world there is a rapidly increasing preva-
lence of diabetes and obesity in the population, resulting in rising
levels of the incidence in diabetic ulcers [59]. These ulcers have a
major impact on both the quality of life and patient morbidity. They
are also extremely costly to healthcare services. Various non-
biological treatments are used to improve the healing of diabetic ul-
cers, such as off-loading of pressure, but patient compliance can be
difﬁcult and treatments are not always effective. As a result a largenumber of these diabetic ulcers fail to heal or healing takes place
over a very protracted period of time. This manifests not only in in-
creased health care costs, but in a larger number of lower limb ampu-
tations and a signiﬁcantly shortened life expectancy of the patient.
The STZ diabetic rat studies [7] support the idea of Cx43 as a potential
therapeutic target in human diabetic wound healing. One group has
also reported a persistence of Cx43 protein in wound edge keratino-
cytes from biopsies of human diabetic ulcers [9]. However, whilst
there have been reports of disrupted cell proliferation and elevated
communication in cultures of human diabetic ﬁbroblasts [97,98], ex-
amination of Cx43 and Cx26 mRNA and protein in keratinocytes
from human diabetic and non-diabetic skin biopsies revealed no dif-
ferences in expression [99]. Subsequently the localization and levels
of Cx43 were shown to be the same in cultures of keratinocytes and
ﬁbroblasts derived from groups of control and diabetic human biop-
sies, as shown by immunostaining and Western blot analysis [34]. If
Cx43 expression is indeed abnormal in human diabetic wounds it is
possible that targeting its expression may improve the healing pro-
cess in these diabetic wounds.
6. Hemichannels and mimetic peptides in wound healing
Intercellular gap junction channels are formed by the docking of two
connexons, or “hemichannels,” one provided by each cell. Gap junction-
al communication has been studied for many years and we are gaining
an increasing understanding of its roles in embryonic development, ho-
meostasis and disease conditions. Further, roles for undocked connex-
ons in signalling are becoming increasingly accepted [100]. Transient
opening of a hemichannel may allow the extracellular release of signal-
lingmolecules such as ATP into the extracellular spacewhen cells or tis-
sues are under stress [101]. However, if the connexons open for too long
the cells will be compromised and die, and excessive hemichannel
opening may be a reason for cell death in some forms of tissue injury.
Preventing or reducing the opening of connexons in different stress
or injury conditions may be beneﬁcial. Connexon opening has been
reported to be rapidlymodiﬁed by application of short stretches of pep-
tide that mimetically match the extracellular loops of connexins [102–
105], which in the short term will block connexon opening but in the
longer term will prevent connexon docking to form gap junctions
[106]. Because the extracellular loops are so highly conserved between
different connexin isoforms the most commonly used peptides, GAP26
and GAP27, from Cx43 and Cx32 are effective on many different con-
nexins [44,102,107,108]. However, it is not just connexon opening
and docking that has been reported to be affected by application of mi-
metic peptides. Other studies have suggested that the peptides can
block the communication properties of docked gap junctions without
affecting their structure [109]. As such application of these peptides
may affect connexon opening, docking and gap junctional communica-
tion in a variety of different types of connexin [110].
Recently mimetic peptides have been applied to a variety of cul-
ture models of wound healing with some intriguing ﬁndings. Applica-
tion of both GAP26 and Gap27 to cultures of human ﬁbroblasts or
keratinocytes reduced gap junction communication within 1.5 h,
which returned within 8 h. In scratch wound assays of these cell cul-
tures, Cx43 was found to naturally downregulate in the wound edges,
and adding the peptide every 12 h over a 5 day period increased the
rate of migration [110]. Extensions of this work to 3D cultures models
of human and porcine cell wound healing have been used to compare
effects of the peptides on cells from donors of different ages and dia-
betic backgrounds [34,111]. It was found that the peptides accelerat-
ed the migration of both infant and adult ﬁbroblasts and
keratinocytes in scratch wound assays [34,112]. Interestingly the pep-
tides were unable to enhance the migration of diabetic ﬁbroblasts or
keratinocytes in early passages of culture but did have an effect on
very late passages [34]. It is not clear why the early passages of dia-
betic cells did not respond to the peptides as the authors reported
2073D.L. Becker et al. / Biochimica et Biophysica Acta 1818 (2012) 2068–2075no differences in the levels of Cx43 between diabetic cells and control
cells as shown by immunostaining and Western blot [34]. However,
they also reported that the GAP27 peptide induced an elevation in
the phosphorylation of Cx43 at serine 368, which is known to alter
Cx43 conductance, and it has been suggested that this change in con-
ductance may be required for normal wound healing. These ﬁndings
do not entirely ﬁt with those from the STZ diabetic rat where Cx43
was found to be abnormally over-expressed in non-migratory
wound edge keratinocytes and needed to be eliminated in order for
them to migrate [7]. Normal levels of Cx43 in cultures of human dia-
betic ﬁbroblasts and keratinocytes does not help to explain their fail-
ure to respond to mimetic peptide treatments. There is an evident
need for more research in order to better understand the roles of con-
nexins in diabetic wound healing.
An alternative peptide approach has been to target the interaction
between the C-terminal tail of Cx43 with proteins such as Zonular
Occludin-1 (ZO-1) by utilizing the internalization protein antennapedia
linked to the last 9 amino acids, RPRPDDLEI, of the Cx43 tail (named
ACT1) [113]. The peptide will bind to the PDZ2 domain on ZO-1 and
compete out its bindingwith the Cx43 C-tail. In addition it can compete
out alternative Cx43 C-tail interactions with the matricellular protein
CCN3 (associated with gliomas and tissue response to injury)
[114,115] 14–3–3 proteins [116] and protein kinases [117]. The result-
ing effect on Cx43 of ACT1 treatment appears is reported to stabilize
Cx43 in the cell membrane resulting in the formation of larger plaques
[113] whilst isolating it from cytoplasmic tail interactions [118]. When
applied to skin lesions in animal models ACT1 is said to have very sim-
ilar affects to the Cx43 antisense in terms of speeding up the rate of
healing whilst reducing scar formation [118–120]. ACT1 applied to
cryo-injuries of the ventricle of the heart reportedly resulted in reduced
association of Cx43 with ZO-1 in the injury border zone and a subse-
quent reduction in arrhythmias [121] with similarities in repair being
compared to that of cutaneous healing [122].
7. Conclusions
Connexins play a pivotal role in a variety of aspects of the acute
wound healing process. By manipulating them in different ways it is
possible to accelerate and improve the normal healing process by
speeding up the phenotypic change of cells to a migratory phenotype
whilst at the same time dampening down some of the potentially
negative aspects of the normal inﬂammatory response to injury
resulting in faster healing and reduced scar formation.
Accelerating acute healing is not however, where the main chal-
lenge lies. Initiating healing when it has stalled in various types of
chronic wounds is the real challenge. Diabetic wound healing offers
a substantial unmet clinical need [1–3]. Trying to understand why
these chronic wounds fail to heal and the potential involvement of
connexins is intriguing, although the story in diabetic tissues is not
yet clear. Animal models of diabetes suggest that connexin function
can be manipulated by antisense to augment healing, thus offering
promise that a variety of connexin modulation therapies currently
in development may have a role in treating the human disease.
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